mRNA vaccine for EBV-related cancers
Treatments studied
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests an mRNA vaccine to treat advanced cancers linked to the Epstein-Barr virus, such as nasopharyngeal cancer, NK/T-cell lymphoma, and stomach cancer. The vaccine teaches your immune system to fight the virus and the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced cancer that is positive for Epstein-Barr virus.
- You have tried at least 2 standard treatments that did not work (for Phase 1) or at least 1 platinum chemo and an immunotherapy (for Phase 2).
- You are well enough to be up and about (ECOG score 0-2).
- Your organs (like liver, kidneys, and heart) are working well enough.
- You do not have other uncontrolled cancers, serious infections, or heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA-based treatment for people with Epstein-Barr virus (EBV) related diseases, such as certain cancers or EBV illness after a transplant. The goal is to see if the treatment can help your immune system fight the virus and the disease.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
This trial tests an mRNA vaccine that may help prevent Epstein-Barr virus (EBV) infections and related diseases after a stem cell transplant. It is for people who have received or will receive a donor stem cell transplant.
This early-stage trial tests an experimental vaccine designed to train your immune system to fight EBV (Epstein-Barr virus), a virus that can contribute to certain lymphomas in people with HIV. You would receive this vaccine as an add-on treatment if standard chemotherapy hasn't fully controlled your lymphoma.
Hear when a new EBV-associated Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.